Buscar
Mostrando ítems 11-20 de 21
The 2022 symposium on dementia and brain aging in low- and middle-income countries: Highlights on research, diagnosis, care, and impact
(Alzheimer’s & Dementia, 2024-02)
Two of every three persons living with dementia reside in low- and middle-income
countries (LMICs). The projected increase in global dementia rates is expected to
affect LMICs disproportionately. However, the majority ...
Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity
(JAMA Netw Open., 2023)
Cerebrospinal fluid (CSF) and plasma biomarkers can detect biological evidence of Alzheimer disease (AD), but their use in low-resource environments and among minority ethnic groups is limited. To assess validated plasma ...
Current status and challenges of stem cell treatment for Alzheimer’s disease
(Journal of Alzheimer’s Disease, 2021)
Neurodegenerative diseases called tauopathies, such as Alzheimer’s disease (AD), frontotemporal dementia, progressive supranuclear palsy, and Parkinson’s disease, among others, are characterized by the pathological processing ...
Prediction of dementia risk in low-income and middleincome countries (the 10/66 Study): an independent external validation of existing models
(Elsevier Ltd., 2020-04)
To date, dementia prediction models have been exclusively developed and tested in high-income countries (HICs). However, most people with dementia live in low-income and middle-income countries (LMICs), where dementia risk ...
Dementia attributable healthcare utilizations in the Caribbean versus United States
(Journal of Alzheimer's Disease, 2023-11-07)
Despite the high burden of Alzheimer's disease and other dementias among the Hispanic population worldwide, little is known about how dementia affects healthcare utilizations among this population outside of the US, in ...
FMNL2 regulates gliovascular interactions and is associated with vascular risk factors and cerebrovascular pathology in Alzheimer’s disease
(Acta Neuropathologica (2022) 144:59–79, 2022-05-24)
Alzheimer’s disease (AD) has been associated with cardiovascular and cerebrovascular risk factors (CVRFs) during middle
age and later and is frequently accompanied by cerebrovascular pathology at death. An interaction ...
Progranulin mutations in clinical and neuropathological Alzheimer’s disease
(Alzheimers Dement., 2022-12-10)
Progranulin (GRN) mutations occur in frontotemporal lobar degeneration
(FTLD) and in Alzheimer’s disease (AD), often with TDP-43 pathology.
We determined the frequency of rs5848 and rare, pathogenic GRN mutations
in two ...
Apolipoprotein E (APOE) genotype, dementia, and memory performance among Caribbean Hispanic versus US populations
(Alzheimer's Association, 2022-06-04)
Apolipoprotein E (APOE) is considered the major susceptibility gene for developing Alzheimer's disease. However, the strength of this risk factor is not well established across diverse Hispanic populations. We investigated ...
Latin American initiative for lifestyle intervention to prevent cognitive decline (LatAm-FINGERS): study design and harmonization
(Alzheimer's Association®, 2023-05-19)
Latin American Initiative for Lifestyle Intervention to Prevent Cognitive Decline (LatAm-FINGERS) is the first non-pharmacological multicenter randomized clinical trial (RCT) to prevent cognitive impairment in Latin America ...
Interpretable Classification of Tauopathies with a Convolutional Neural Network Pipeline Using Transfer Learning and Validation against Post-Mortem Clinical Cases of Alzheimer’s Disease and Progressive Supranuclear Palsy
(MDP, 2022-11-22)
Neurodegenerative diseases, tauopathies, constitute a serious global health problem.
The etiology of these diseases is unclear and an increase in their incidence has been projected
in the next 30 years. Therefore, the ...